Merck & Co. (Seite 6)
eröffnet am 24.12.20 12:31:49 von
neuester Beitrag 08.01.24 18:25:50 von
neuester Beitrag 08.01.24 18:25:50 von
Beiträge: 73
ID: 1.336.969
ID: 1.336.969
Aufrufe heute: 1
Gesamt: 11.193
Gesamt: 11.193
Aktive User: 0
ISIN: US58933Y1055 · WKN: A0YD8Q · Symbol: 6MK
120,80
EUR
+0,17 %
+0,20 EUR
Letzter Kurs 17.05.24 Tradegate
Neuigkeiten
Merck & Co Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
15.05.24 · wO Newsflash |
15.05.24 · Business Wire (engl.) |
13.05.24 · wO Newsflash |
13.05.24 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
2,25 | +63,04 | |
0,8000 | +45,45 | |
1,0000 | +42,86 | |
6,2500 | +24,75 | |
2,5440 | +15,22 |
Wertpapier | Kurs | Perf. % |
---|---|---|
114,60 | -13,61 | |
23,700 | -19,52 | |
28,60 | -24,06 | |
1,3500 | -25,62 | |
0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 69.738.538 von faultcode am 29.10.21 01:05:05und durch:
der RSI|14 ist aber wieder dermaßen heiß gelaufen bei diesem Dickschiff (und Nicht-Meme-Stock), daß ich mit einem Retest der ~USD88 und Konso erstmal rechne
der RSI|14 ist aber wieder dermaßen heiß gelaufen bei diesem Dickschiff (und Nicht-Meme-Stock), daß ich mit einem Retest der ~USD88 und Konso erstmal rechne
Q3: Merck & Co mit unerwartet gutem Quartal - Ziele angehoben
https://www.wallstreet-online.de/nachricht/14593294-merck-co…
...
Unter dem Strich konnte Merck & Co seinen Gewinn aus dem fortgeführten Geschäft mit knapp 4,6 Milliarden Dollar nahezu verdoppeln. Im Gesamtjahr peilt der Konzern nun einen Umsatzanstieg auf 47,4 bis 47,9 Milliarden Dollar an. Das bereinigte EPS soll bei 5,65 bis 5,70 Dollar herauskommen. Die Amerikaner hatten zuletzt Ende Juli ihre Ziele wegen der Abspaltung des Pharmaunternehmens Organon angepasst.
=> +6% => Jahreshoch:
https://www.wallstreet-online.de/nachricht/14593294-merck-co…
...
Unter dem Strich konnte Merck & Co seinen Gewinn aus dem fortgeführten Geschäft mit knapp 4,6 Milliarden Dollar nahezu verdoppeln. Im Gesamtjahr peilt der Konzern nun einen Umsatzanstieg auf 47,4 bis 47,9 Milliarden Dollar an. Das bereinigte EPS soll bei 5,65 bis 5,70 Dollar herauskommen. Die Amerikaner hatten zuletzt Ende Juli ihre Ziele wegen der Abspaltung des Pharmaunternehmens Organon angepasst.
=> +6% => Jahreshoch:
Antwort auf Beitrag Nr.: 69.487.483 von Malecon am 03.10.21 00:28:52Short covering mMn: +1.5M Aktien von Mitte August bis Mitte September mehr geshortet: https://finance.yahoo.com/quote/MRK/key-statistics?p=MRK
Am Freitag war an der NYSE mit > 101M Stück Umsatz das höchste Volumen seit August 2016!
Warum sollten die Käufer das derzeitige Kursniveau so schnell wieder räumen, außer aus molnupiravir sollte nichts werden?
Ansonsten:
...
While we project the drug should post sales over $3 billion in 2022, we expect sales to fall rapidly by 2024 when the pandemic will likely be under better control due to higher vaccine utilization. The lack of a long duration of sales for molnupiravir (as well as profit sharing with Ridgeback Biotherapeutics) limits the drug’s valuation gains for Merck....
https://www.morningstar.com/stocks/xnys/mrk/quote
Am Freitag war an der NYSE mit > 101M Stück Umsatz das höchste Volumen seit August 2016!
Warum sollten die Käufer das derzeitige Kursniveau so schnell wieder räumen, außer aus molnupiravir sollte nichts werden?
Ansonsten:
...
While we project the drug should post sales over $3 billion in 2022, we expect sales to fall rapidly by 2024 when the pandemic will likely be under better control due to higher vaccine utilization. The lack of a long duration of sales for molnupiravir (as well as profit sharing with Ridgeback Biotherapeutics) limits the drug’s valuation gains for Merck....
https://www.morningstar.com/stocks/xnys/mrk/quote
Vorsicht, die Form der letzten Chartkerze (typischer Abverkauf) und die große Lücke nach unten deuten auf eine Überteibung nach oben hin:
Wer am Freitag seine Gewinne nicht mitgenommen hat, muss aufpassen.
Wer am Freitag seine Gewinne nicht mitgenommen hat, muss aufpassen.
Antwort auf Beitrag Nr.: 69.487.180 von Wuzel2000 am 02.10.21 22:05:36ich würden einfach den bisherigen Analysten-Konsens nehmen als unterste Stufe. Nächste Woche kommt vermutlich mehr nach:
--> ~USD93
https://www.marketbeat.com/stocks/NYSE/MRK/price-target/
--> ~USD93
https://www.marketbeat.com/stocks/NYSE/MRK/price-target/
Was dürfte nun das Kursziel nach oben sein , nach der Top Nachricht
1.10.
Vaccine Stocks Shed $84 Billion as Merck Pill Adds to Rough Week
https://finance.yahoo.com/news/vaccine-stocks-shed-84-billio…
For the world’s leading Covid-19 vaccine makers, news that Merck & Co.’s experimental pill cuts the risk of hospitalization and death in half was the latest blow in a very bad week.
Stocks including Moderna Inc. and BioNTech SE have shed about $84 billion in combined value this week in the aftermath of a stock market slump that sent the two companies to their lowest level since July.
Selling accelerated on Friday, with BioNTech and Moderna each declining as much as 16% in New York as Merck delivered the news on its experimental pill that Wall Street called a “game changer.”
The drug, called molnupiravir, reduced the risk of hospitalization or death by 50% in a study, raising concerns about the long-term revenues for companies providing inoculations.
“You have news of a new player coming into the market with a much less rigorous treatment and that alone has to dampen the day for the rest of the field whether they’re vaccines or drugs administered in the hospital for Covid-19,” said Jared Holz, managing director of healthcare equities at Oppenheimer & Co. “The vaccine revenue numbers over the next few years would have to come down.”
Wall Street analysts had forecast Moderna’s Covid-19 vaccines will bring in more than $20 billion in sales this year, before dropping to $6.1 billion by 2025.
...
Vaccine Stocks Shed $84 Billion as Merck Pill Adds to Rough Week
https://finance.yahoo.com/news/vaccine-stocks-shed-84-billio…
For the world’s leading Covid-19 vaccine makers, news that Merck & Co.’s experimental pill cuts the risk of hospitalization and death in half was the latest blow in a very bad week.
Stocks including Moderna Inc. and BioNTech SE have shed about $84 billion in combined value this week in the aftermath of a stock market slump that sent the two companies to their lowest level since July.
Selling accelerated on Friday, with BioNTech and Moderna each declining as much as 16% in New York as Merck delivered the news on its experimental pill that Wall Street called a “game changer.”
The drug, called molnupiravir, reduced the risk of hospitalization or death by 50% in a study, raising concerns about the long-term revenues for companies providing inoculations.
“You have news of a new player coming into the market with a much less rigorous treatment and that alone has to dampen the day for the rest of the field whether they’re vaccines or drugs administered in the hospital for Covid-19,” said Jared Holz, managing director of healthcare equities at Oppenheimer & Co. “The vaccine revenue numbers over the next few years would have to come down.”
Wall Street analysts had forecast Moderna’s Covid-19 vaccines will bring in more than $20 billion in sales this year, before dropping to $6.1 billion by 2025.
...
Expansion Breakout in Vorbereitung -- und das bei diesem Dickschiff
Haben heute eine Notfallzulassung in US beantragt 👍
29.9.
Merck Says Its Covid-19 Antiviral Pill Looks Good Against Variants
https://www.marketwatch.com/articles/merck-covid-19-antivira…
Merck presented a study at a medical conference early Wednesday showing that its experimental Covid-19 antiviral is active against variants of the virus that causes the sickness.
The Merck product, known as molnupiravir, is one of a number of antiviral pills under development to treat and even prevent Covid-19.
Pivotal data on some of the pills, including those from Merck (ticker: MRK) and from Pfizer (PFE), is likely to be available soon. Executives from both companies have said they plan to file for emergency-use authorization before the end of the year.
...
Merck Says Its Covid-19 Antiviral Pill Looks Good Against Variants
https://www.marketwatch.com/articles/merck-covid-19-antivira…
Merck presented a study at a medical conference early Wednesday showing that its experimental Covid-19 antiviral is active against variants of the virus that causes the sickness.
The Merck product, known as molnupiravir, is one of a number of antiviral pills under development to treat and even prevent Covid-19.
Pivotal data on some of the pills, including those from Merck (ticker: MRK) and from Pfizer (PFE), is likely to be available soon. Executives from both companies have said they plan to file for emergency-use authorization before the end of the year.
...
15.05.24 · wO Newsflash · AES |
15.05.24 · Business Wire (engl.) · Merck & Co |
13.05.24 · wO Newsflash · Carl Zeiss Meditec |
13.05.24 · Business Wire (engl.) · Merck & Co |
09.05.24 · Business Wire (engl.) · Merck & Co |
08.05.24 · wO Newsflash · BMW |
08.05.24 · Accesswire · Merck & Co |
08.05.24 · Business Wire (engl.) · Merck & Co |
04.05.24 · wO Chartvergleich · American Express |
01.05.24 · dpa-AFX · Bayer |